文献速递冠心病瓣膜病与结构性心脏病

微血栓是COVID-19心脏损伤的主要原因:一项病理学研究

Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study.
PubMed 文献 · Circulation · 2021-01-22

该研究对意大利贝加莫40例死于COVID-19的住院患者心脏进行系统病理分析,按有无急性心肌细胞坏死分组探究损伤机制。结果显示35%的心脏存在心肌细胞坏死,其中78.6%的坏死病例检出心脏血栓,最常见为心肌微血管微血栓;微血栓的纤维蛋白和C5b-9免疫染色显著多于对照血栓。

要点

  • COVID-19住院死亡患者中35%存在心肌细胞坏死,以左心室为主。
  • 坏死病例中78.6%检出心脏血栓,64.3%为心肌微血管微血栓。
  • 微血栓成分与阴性对照血栓及STEMI抽吸血栓显著不同。

核心结论

  • 心肌细胞坏死最常见的病理原因是微血栓。
  • 微血栓成分不同于COVID-19阴性者的心肌内血栓栓塞和COVID-19阳性及阴性STEMI患者的冠状动脉血栓。
  • 针对性的抗血栓策略可能有助于对抗COVID-19感染的心脏效应。

研究设计与样本

  • 对意大利贝加莫40例死于COVID-19的住院患者心脏进行系统病理分析。
  • 按有无急性心肌细胞坏死分组,确定心脏损伤的潜在机制。
  • 将COVID-19阳性尸检心脏微血栓与COVID-19病例心肌内血栓栓塞及STEMI患者PCI抽吸血栓进行成分比较。

主要发现

  • 40颗心脏中14颗(35%)存在心肌细胞坏死,以左心室为主。
  • 坏死组倾向女性、慢性肾病及症状至入院时间更短。
  • 严重冠心病(>75%横截面狭窄)发生率在有无坏死组间无显著差异。
  • 14例坏死中3例(21.4%)为急性心肌梗死(坏死面积≥1 cm2),11例(78.6%)为局灶性坏死(>20个坏死心肌细胞,面积≥0.05 mm2但<1 cm2)。
  • 14例坏死中11例(78.6%)存在心脏血栓:2例(14.2%)为心外膜冠状动脉血栓,9例(64.3%)为心肌毛细血管、小动脉和小肌性动脉微血栓。

关键数值与推荐

  • 急性心肌梗死定义为坏死面积≥1 cm2。
  • 局灶性心肌细胞坏死定义为>20个坏死心肌细胞且面积≥0.05 mm2但<1 cm2。
  • 严重冠心病定义为>75%横截面狭窄。
  • 微血栓纤维蛋白和终末补体C5b-9免疫染色显著多于COVID-19阴性者心肌内血栓栓塞及抽吸血栓。
  • COVID-19阳性与阴性STEMI患者抽吸血栓成分无显著差异。

临床怎么用

  • COVID-19住院患者心脏损伤应考虑微血栓机制而非仅大血管冠脉病变。
  • 对COVID-19相关心脏损伤可评估针对性抗血栓策略的潜在价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiac injury is common in patients who are hospitalized with coronavirus disease 2019 (COVID-19) and portends poorer prognosis. However, the mechanism and the type of myocardial damage associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remain uncertain. METHODS: We conducted a systematic pathological analysis of 40 hearts from hospitalized patients dying of COVID-19 in Bergamo, Italy, to determine the pathological mechanisms of cardiac injury. We divided the hearts according to presence or absence of acute myocyte necrosis and then determined the underlying mechanisms of cardiac injury. RESULTS: Of the 40 hearts examined, 14 (35%) had evidence of myocyte necrosis, predominantly of the left ventricle. Compared with subjects without necrosis, subjects with necrosis tended to be female, have chronic kidney disease, and have shorter symptom onset to admission. The incidence of severe coronary artery disease (ie, >75% cross-sectional narrowing) was not significantly different between those with and without necrosis. Three of 14 (21.4%) subjects with myocyte necrosis showed evidence of acute myocardial infarction, defined as ≥1 cm2 area of necrosis, whereas 11 of 14 (78.6%) showed evidence of focal (>20 necrotic myocytes with an area of ≥0.05 mm2 but <1 cm2) myocyte necrosis. Cardiac thrombi were present in 11 of 14 (78.6%) cases with necrosis, with 2 of 14 (14.2%) having epicardial coronary artery thrombi, whereas 9 of 14 (64.3%) had microthrombi in myocardial capillaries, arterioles, and small muscular arteries. We compared cardiac microthrombi from COVID-19-positive autopsy cases to intramyocardial thromboemboli from COVID-19 cases as well as to aspirated thrombi obtained during primary percutaneous coronary intervention from uninfected and COVID-19-infected patients presenting with ST-segment-elevation myocardial infarction. Microthrombi had significantly greater fibrin and terminal complement C5b-9 immunostaining compared with intramyocardial thromboemboli from COVID-19-negative subjects and with aspirated thrombi. There were no significant differences between the constituents of thrombi aspirated from COVID-19-positive and -negative patients with ST-segment-elevation myocardial infarction. CONCLUSIONS: The most common pathological cause of myocyte necrosis was microthrombi. Microthrombi were different in composition from intramyocardial thromboemboli from COVID-19-negative subjects and from coronary thrombi retrieved from COVID-19-positive and -negative patients with ST-segment-elevation myocardial infarction. Tailored antithrombotic strategies may be useful to counteract the cardiac effects of COVID-19 infection.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Pellegrini D, Kawakami R, Guagliumi G, et al. Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study. Circulation. 2021. PMID: 33480806. doi:10.1161/CIRCULATIONAHA.120.051828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。